Bristol Myers Squibb Reports Five-Year CheckMate-238 Data for Adjuvant Opdivo in Melanoma

Bristol Myers Squibb today presented five-year recurrence-free survival data from the Phase 3 CheckMate-238 trial evaluating adjuvant Opdivo (nivolumab) versus ipilimumab in patients with resected stage IIIB-IV melanoma. The data showed that 50% of patients in the Opdivo arm remained recurrence-free at five years compared to 39% in the ipilimumab arm.